(Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention ...
A federal judge has dismissed legal challenges to the Medicare negotiation program brought by Bristol Myers Squibb and Johnson & Johnson, ruling that their claims of unconstitutionality are unfounded.
A federal judge in New Jersey rejected Johnson & Johnson and Bristol Myers Squibb's legal challenges to the Biden administration's Medicare drug price negotiations, ruling that the program is ...
Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow. Its high debt load could turn off some risk ...
Bristol-Myers Squibb's share price reached new all-time highs in 2022, driven by a strong pipeline and new approvals. However, doubts arose about the company's ability to close the patent gap and ...
Bristol Myers Squibb said on Friday that its trial evaluating a combination of cancer treatments failed to meet its primary endpoint. The company’s trial was evaluating the cancer-drug Opdivo ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Bristol Myers Squibb wants patients living with schizophrenia to experience life to the fullest extent possible. That’s why the pharma giant rolled out Live Your PosSCZible, a national campaign ...
A federal judge on Monday threw out legal challenges to the Medicare negotiation program that had been brought by Bristol Myers Squibb and Johnson & Johnson, finding that their claims of ...
Bristol Myers Squibb’s product Eliquis was named among the first 10 drugs eligible for Medicare negotiation, as were Xarelto, Imbruvica and Stelara from Johnson & Johnson.